Minerva Endocrinol
The approval keeps Novo Nordisk's nose in front of its main rival in the GLP-1 market, Eli Lilly, which is also hoping to add MASH to the indications for Wegovy rival Zepbound (tirzepatide), a dual GIP/GLP-1 agonist that has proved better than Wegovy at achieving weight loss in head-to-head trials
Similar findings were reported in studies examining the pharmacokinetics, pharmacodynamics, and safety of RG7697/NNC0090-2746 in 56 patients with T2D who received once-daily subcutaneous injections of 0.25, 0.75, 1.1, 1.5, 2, or 2.5 mg of the co-agonist or placebo for 2 weeks in a randomized, double-blind, dose-escalation study [81]
Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics
Our best foods to eat on semaglutide guide includes specific timing strategies
How to Perform the Perfect Injection Regardless of whether you choose the thigh or the stomach, your technique determines your comfort